Edwards Lifesciences Urges Supreme Court to Clarify Patent Safe Harbor for Drug Development

Edwards Lifesciences has made a direct appeal to the U.S. Supreme Court regarding the interpretation of a drug-development safe harbor intended to prevent patent infringement. The company argues that the Federal Circuit has effectively broadened the scope of this provision through what it terms a “novel misreading” of the law. This plea for intervention aims to clarify legal boundaries for what activities are protected under the safe harbor, a matter that directly impacts pharmaceutical and biotech industries. For further details, visit the full coverage on Law360.